Design Therapeutics, Inc. SEC filings DSGN
Design Therapeutics, Inc. has 268 filings in SEC EDGAR's recent list, going back to Mar 20, 2020. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-3 | Shelf registration | Nov 4, 2026 | — |
| 424B5 | Prospectus supplement | Nov 4, 2026 | — |
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Aug 3, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 3, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 9, 2026 |
| 8-K |
Current report
Other events
|
May 18, 2026 | May 18, 2026 |
| 10-Q | Quarterly report | Apr 28, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Apr 28, 2026 | Apr 28, 2026 |
| DEFA14A | Additional proxy material | Apr 23, 2026 | — |
| DEF 14A | Proxy statement | Apr 23, 2026 | Apr 23, 2026 |
| ARS | Annual report to shareholders | Apr 23, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change
|
Apr 1, 2026 | Mar 31, 2026 |
| S-8 | Employee stock plan registration | Mar 9, 2026 | — |
| 10-K | Annual report | Mar 9, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 9, 2026 | Mar 9, 2026 |
| 8-K |
Current report
Officer or director change
|
Jan 30, 2026 | Jan 29, 2026 |
| 10-Q | Quarterly report | Nov 5, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2025 | Nov 5, 2025 |
| 8-K |
Current report
Officer or director change
|
Sep 10, 2025 | Sep 9, 2025 |
| 10-Q | Quarterly report | Aug 7, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 7, 2025 | Aug 7, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2025 | Jun 10, 2025 |
| EFFECT | Filing | May 16, 2025 | — |
| CORRESP | Letter to the SEC | May 14, 2025 | — |
| UPLOAD | Letter from the SEC | May 13, 2025 | — |
| S-3 | Shelf registration | May 7, 2025 | — |
| 10-Q | Quarterly report | May 7, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 7, 2025 | May 7, 2025 |
| DEFR14A | Filing | Apr 30, 2025 | — |
| ARS | Annual report to shareholders | Apr 24, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 24, 2025 | — |
| DEF 14A | Proxy statement | Apr 24, 2025 | Jun 10, 2025 |
| S-8 | Employee stock plan registration | Mar 10, 2025 | — |
| 10-K | Annual report | Mar 10, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 10, 2025 | Mar 10, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 13, 2025 | Jan 13, 2025 |
| 10-Q | Quarterly report | Nov 7, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2024 | Nov 7, 2024 |
| 10-Q | Quarterly report | Aug 5, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2024 | Aug 5, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2024 | Jun 13, 2024 |
| 10-Q | Quarterly report | May 8, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 8, 2024 | May 8, 2024 |
| ARS | Annual report to shareholders | Apr 25, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 25, 2024 | — |
| DEF 14A | Proxy statement | Apr 25, 2024 | Jun 13, 2024 |
| S-8 | Employee stock plan registration | Mar 19, 2024 | — |
| 10-K | Annual report | Mar 19, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 19, 2024 | Mar 19, 2024 |
| 10-Q | Quarterly report | Nov 13, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2023 | Nov 13, 2023 |
| 8-K |
Current report
Officer or director change
|
Aug 25, 2023 | Aug 25, 2023 |
| 10-Q | Quarterly report | Aug 14, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2023 | Aug 14, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 1, 2023 | May 31, 2023 |
| 10-Q | Quarterly report | May 9, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations
|
May 9, 2023 | May 9, 2023 |
| ARS | Annual report to shareholders | Apr 13, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | Apr 13, 2023 | — |
| DEF 14A | Proxy statement | Apr 13, 2023 | May 31, 2023 |
| S-8 | Employee stock plan registration | Mar 14, 2023 | — |
| 10-K | Annual report | Mar 14, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 14, 2023 | Mar 14, 2023 |
| 10-Q | Quarterly report | Nov 3, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2022 | Nov 3, 2022 |
| 10-Q | Quarterly report | Aug 8, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2022 | Aug 8, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 16, 2022 | Jun 15, 2022 |
| EFFECT | Filing | May 9, 2022 | — |
| 10-Q | Quarterly report | May 9, 2022 | Mar 31, 2022 |
| 8-K |
Current report
Results of operations
|
May 9, 2022 | May 9, 2022 |
| CORRESP | Letter to the SEC | May 5, 2022 | — |
| CORRESP | Letter to the SEC | May 2, 2022 | — |
| UPLOAD | Letter from the SEC | Apr 29, 2022 | — |
| S-3 | Shelf registration | Apr 27, 2022 | — |
| DEFA14A | Additional proxy material | Apr 27, 2022 | — |
| DEF 14A | Proxy statement | Apr 27, 2022 | Jun 15, 2022 |
| 8-K |
Current report
Material agreement
|
Mar 22, 2022 | Mar 18, 2022 |
| S-8 | Employee stock plan registration | Mar 10, 2022 | — |
| 10-K | Annual report | Mar 10, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Results of operations
|
Mar 10, 2022 | Mar 10, 2022 |
| 10-Q | Quarterly report | Nov 9, 2021 | Sep 30, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2021 | Nov 9, 2021 |
| 8-K |
Current report
Officer or director change
|
Aug 20, 2021 | Aug 18, 2021 |
| 10-Q | Quarterly report | Aug 9, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 9, 2021 | Aug 9, 2021 |
| 8-K |
Current report
Officer or director change
|
Aug 6, 2021 | Aug 2, 2021 |
| 8-K |
Current report
Officer or director change
|
Jun 7, 2021 | Jun 3, 2021 |
| 10-Q | Quarterly report | May 10, 2021 | Mar 31, 2021 |
| 8-K |
Current report
Results of operations
|
May 10, 2021 | May 10, 2021 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Mar 30, 2021 | Mar 30, 2021 |
| S-8 | Employee stock plan registration | Mar 26, 2021 | — |
| 424B4 | Prospectus | Mar 26, 2021 | — |
| EFFECT | Filing | Mar 25, 2021 | — |
| CERT | Filing | Mar 24, 2021 | — |
| SEC STAFF LETTER | Filing | Mar 24, 2021 | — |
| 8-A12B | Filing | Mar 23, 2021 | — |
| CORRESP | Letter to the SEC | Mar 23, 2021 | — |
| CORRESP | Letter to the SEC | Mar 23, 2021 | — |
| CORRESP | Letter to the SEC | Mar 22, 2021 | — |
| S-1/A | Amended registration statement | Mar 22, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 18, 2021 | — |
| CORRESP | Letter to the SEC | Mar 16, 2021 | — |
| CORRESP | Letter to the SEC | Mar 5, 2021 | — |
| S-1 | Registration statement | Mar 5, 2021 | — |
| SEC STAFF LETTER | Filing | Feb 23, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 23, 2021 | — |
| D | Filing | Feb 12, 2021 | — |
| DRS | Filing | Jan 26, 2021 | — |
| D/A | Filing | Jun 3, 2020 | — |
| D | Filing | Mar 20, 2020 | — |
Showing 113 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DSGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Carlsbad, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1807120
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.